223
Views
14
CrossRef citations to date
0
Altmetric
Research Article

Jellyfish Antivenoms: Past, Present, and Future

, , , , &
Pages 115-127 | Published online: 05 Dec 2003
 

Abstract

If snake antivenoms are considered orphan drugs, then jellyfish antivenoms are the poorest of the orphans. Despite the diversity, ubiquity and toxicity of the venomous cnidarians, only a single antivenom is available for jellyfish stings worldwide. That antivenom, an ovine whole IgG product, is directed against the ‘box’ jellyfish, Chironex fleckeri, and is manufactured by CSL Limited (Melbourne, Australia). It also neutralises the venom of closely related cubozoans such as Chiropsalmus quadrigatus. The recognition of the life‐threatening effects of various other jellyfish demonstrates the need for broadening the specificity of the existing product and/or developing additional specific jellyfish antivenoms. These emerging threats include the irukandji syndrome, due to Carukia barnesi and other carybdeids, as well as those from scyphozoans such as Stomolophus spp. The role of ancillary drug therapy, in addition to, or instead of, antivenoms remains controversial. This review will consider the development of jellyfish antivenoms, their clinical utility and future developments in the field.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.